Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cisapride Monohydrate

FDA-approved product (tablet, oral), marketed as Propulsid, Propulsid Quicksolv.

Registered studies
5
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cisapride Monohydrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gastrointestinal disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Propulsives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cisapride Monohydrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cisapride Monohydrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease

    NCT01281553 · start 2003-09

    Registered record
    Registry ID
    NCT01281553
    Conditions
    Gastroesophageal Reflux
    Interventions
    Placebo; Cisapride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-09
    Completion
    2003-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux
    InterventionPlacebo; Cisapride
    PhasePhase 4
    Registry statusTerminated

  • An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus

    NCT01286090 · start 2003-07

    Registered record
    Registry ID
    NCT01286090
    Conditions
    Gastroparesis; Diabetes Mellitus
    Interventions
    Cisapride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-07
    Completion
    2003-10
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroparesis; Diabetes Mellitus
    InterventionCisapride; Placebo
    PhasePhase 4
    Registry statusTerminated

  • An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options

    NCT01281540 · start 2003-05

    Registered record
    Registry ID
    NCT01281540
    Conditions
    Gastroparesis
    Interventions
    Cisapride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-05
    Completion
    2003-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroparesis
    InterventionCisapride; Placebo
    PhasePhase 4
    Registry statusTerminated

  • A Study of Cisapride in Premature Infants With Feeding Problems

    NCT01281566 · start 2003-03

    Registered record
    Registry ID
    NCT01281566
    Conditions
    Infant, Premature; Infant, Newborn
    Interventions
    Placebo; Cisapride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-03
    Completion
    2003-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfant, Premature; Infant, Newborn
    InterventionPlacebo; Cisapride
    PhasePhase 4
    Registry statusTerminated

  • Limited Access Protocol for the Use of Oral Cisapride

    NCT02524496 · start 2001-03

    Registered record
    Registry ID
    NCT02524496
    Conditions
    Gastroparesis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-03
    Completion
    2011-03
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroparesis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted